Literature DB >> 32149722

Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.

David Z Cherney1, Katherine R Tuttle2,3,4.   

Abstract

Entities:  

Keywords:  Diabetes Mellitus; Diabetic Nephropathies; Glucagon-Like Peptide 1; Hypoglycemic Agents; Liraglutide; Type 2; albuminuria; chronic kidney disease; diabetes mellitus; diabetic nephropathy; glomerular filtration rate

Mesh：

Substances：

Year:  2020        PMID： 32149722      PMCID： PMC7133122          DOI： 10.2215/CJN.01260120

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Johannes F E Mann; Vivian A Fonseca; Neil R Poulter; Itamar Raz; Thomas Idorn; Søren Rasmussen; Bernt Johan von Scholten; Ofri Mosenzon
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

3.  Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).

Authors:  Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Alan G Zimmermann; Brad Woodward; Fady T Botros
Journal:  Diabetes Obes Metab       Date:  2019-03-29       Impact factor: 6.577

4.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Fady T Botros; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

Review 5.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

6.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Authors:  Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Robert S Busch; Alan G Zimmermann; D Bradley Woodward; Fady T Botros
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-14       Impact factor: 32.069

Review 7.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

8.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

9.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.